drugset / Trial / NCT05859464
A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors
Phase 1
Terminated
34 enrolled
Zai Lab
Merck Sharp & Dohme LLC · collabZai Biopharmaceutical (Shanghai) Co., Ltd. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ZL-1218 as a single agent and as combination therapy in subjects with advanced solid tumor malignancies.
Timeline
- Start
- 2023-07-24
- Primary completion
- 2025-08-28
- Completion
- 2025-08-28
Outcome
Outcome not reported
Stopped (Business): “Sponsor Decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | ZL-1218 | Unknown | — | — |